Key facts
- BOOST Pharma’s last known valuation is $580K (May 2024).
- It has raised $5.1M; the latest was Later Stage VC ($4.4M) in Nov 2025.
- Notable investors include Industrifonden, BioInnovation Institute, Danish Innovation Foundation, KDventures, Karolinska Development — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BOOST Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for BOOST Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BOOST Pharma
Developer of stem cell therapy designed for the treatment of osteogenesis imperfecta. The company's treatment is based on novel mesenchymal stem cells that have high bone-forming capabilities which once injected will migrate to the bone of patients where they will engraft, and start the bone formation, enabling clinicians to address the disease at the earliest possible stage and increase the benefits for the patient in later years.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2019
- Employees
- 6
- Website
- boostpharma.com/
- Ownership
- Privately Held (backing)
BOOST Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BOOST Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BOOST Pharma in its N-PORT filings yet. We sweep new filings monthly.